ArticleFrontiers in psychiatry2026
County-level variation and trajectories in ADHD medication dispensing among Norwegian children and adolescents, 2005-2022: a nationwide prescription register study.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: National trends in ADHD medication use in Norway have recently been described. Less is known about whether children and adolescents in different counties have followed similar or diverging medication-dispensing trajectories over time. We therefore examined county-level variation and county-level trajectories in ADHD medication dispensing among Norwegian children and adolescents from 2005 to 2022. Methods: We conducted a nationwide retrospective drug-utilisation study using aggregated data from the Norwegian Prescription Database and population denominators from Statistics Norway. The study included individuals aged 6-17 years who redeemed at least one prescription for an ADHD medication between 2005 and 2022. Annual dispensing prevalence was calculated by county, sex, and age group and expressed as users per 1,000 inhabitants. Analyses were stratified into children aged 6-11 years and adolescents aged 12-17 years. To quantify regional variation, we calculated the lowest and highest county rates, absolute rate differences, and high-to-low county rate ratios. Results: ADHD medication dispensing increased in all sex and age strata, but county-level trajectories differed over time. In 2022, dispensing prevalence among girls aged 6-11 years ranged from 4.6 per 1,000 inhabitants in Oslo to 15.1 per 1,000 in Møre og Romsdal, corresponding to a 3.25-fold difference. Among boys aged 6-11 years, rates ranged from 14.6 per 1,000 in Oslo to 39.9 per 1,000 in Nordland, corresponding to a 2.74-fold difference. Among adolescents aged 12-17 years, rates ranged from 15.3 per 1,000 in Agder to 35.2 per 1,000 in Trøndelag among girls, and from 25.1 per 1,000 in Oslo to 62.4 per 1,000 in Trøndelag among boys, corresponding to 2.30-fold and 2.49-fold differences, respectively. Conclusions: This study extends previous Norwegian register-based work by showing substantial county-level variation in ADHD medication dispensing among children and adolescents. National averages may conceal important regional differences in recognition, referral pathways, diagnostic practice, treatment thresholds, prescribing practice, or service organisation. Further studies linking prescription data with diagnostic, clinical, service-level, and socioeconomic information are needed to clarify the drivers and consequences of these regional differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.